First-in-class CHK1 inhibitor antibody-drug conjugate overcomes limitations of current ADC payloads and provides a new option for HER2-positive and TOP1 inhibitor-resistant tumors

Herceptin (trastuzumab) - Roche

CHK1i ADC - Cancentus Pharma

https://www.abstractsonline.com/pp8/#!/21436/presentation/5384

Thanos D. Halazonetis1; Giacomo G. Rossetti2; Daniela Carraturo3; Michalis Petropoulos2; Camilla Trugenberger4; Theodoros Rampias5; Dennis Gillingham3

Mar 18, 2026